This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Lercanidipine hydrochloride oral

Updated 2 Feb 2023 | Calcium channel blockers


Oral formulations of lercanidipine hydrochloride.

Drugs List

  • lercanidipine 10mg tablets
  • lercanidipine 20mg tablets
  • ZANIDIP 10mg tablets
  • ZANIDIP 20mg tablets
  • Therapeutic Indications


    Treatment of mild to moderate essential hypertension



    Initially 10mg orally once daily, at least 15 minutes before a meal.

    Dosage may be increased to 20mg according to patient response.

    Titration should be gradual as it may take about 2 weeks to achieve maximal response.

    Doses above 20 to 30mg daily are unlikely to increase antihypertensive effect, and side effects may be increased.

    Patients with Renal Impairment

    Mild to moderate renal impairment
    Although the recommended dose may be tolerated in these patients care should be shown when approaching a 20mg daily dose.

    Patients with Hepatic Impairment

    Mild to moderate hepatic impairment
    Although the recommended dose may be tolerated in these patients, an increase to 20mg daily must be used with caution.


    Children under 18 years
    Aortic stenosis
    Left ventricular outflow obstruction
    Renal impairment - glomerular filtration rate below 30ml/minute
    Severe hepatic impairment
    Uncontrolled congestive cardiac failure
    Unstable angina
    Within 1 month of a myocardial infarction

    Precautions and Warnings

    Glucose-galactose malabsorption syndrome
    Hepatic impairment
    Ischaemic heart disease
    Lactose intolerance
    Non-paced sinus node dysfunction
    Reduced left ventricular function
    Renal dialysis
    Renal impairment

    Advise ability to drive/operate machinery may be affected by side effects
    Contains lactose
    Advise patient to moderate alcohol intake during treatment
    Advise patient to avoid grapefruit products
    Female: Ensure adequate contraception during treatment

    Very rarely patients with pre-existing angina pectoris may experience increased frequency, duration or severity of attacks.

    Lercanidipine is associated with cloudy peritoneal effluent in patients on peritoneal dialysis. Cloudy peritoneal effluent can be mistaken for infective peritonitis with unnecessary hospitalisation and empiric antibiotic administration.

    Pregnancy and Lactation


    Lercanidipine hydrochloride is contraindicated during pregnancy.

    The manufacturer does not recommend using lercanidipine during pregnancy or in women of childbearing-potential not using contraception. At the time of writing there is limited published information regarding the use of lercanidipine hydrochloride during pregnancy. Potential risks are unknown.


    Lercanidipine hydrochloride is contraindicated during breastfeeding.

    Use of lercanidipine hydrochloride when breastfeeding is contraindicated by the manufacturer. The presence of lercanidipine hydrochloride in human breast milk and effects on exposed infants are unknown.

    Side Effects

    Abdominal pain
    Aggravation of angina
    Angina pectoris
    Chest pain
    Gingival hypertrophy
    Hypersensitivity reactions
    Increases in serum transaminases (reversible)
    Myocardial infarction
    Peripheral oedema
    Peritoneal cloudy effluent
    Precordial pain
    Urinary dysfunction


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: November 2019

    Reference Sources

    Summary of Product Characteristics: Zanidip 10mg tablets. Recordati Pharmaceuticals Ltd. Revised November 2018.
    Summary of Product Characteristics: Zanidip 20mg tablets. Recordati Pharmaceuticals Ltd. Revised November 2018.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.